NUVL Quote, Financials, Valuation and Earnings

Glaukos Corp. has a net margin of -- compared to Nuvalent, Inc.'s net margin of -93.39%. Nuvalent, Inc.'s return on equity of -38.24% beat Glaukos Corp.'s return on equity of -25.22%.

Nuvalent, Inc. has a consensus price target of $142.65, signalling upside risk potential of 41.94%. On the other hand Glaukos Corp. has an analysts' consensus of $134.79 which suggests that it could grow by 12.07%. Given that Nuvalent, Inc. has higher upside potential than Glaukos Corp., analysts believe Nuvalent, Inc. is more attractive than Glaukos Corp..

Nuvalent, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Glaukos Corp. has a beta of 0.705, suggesting its less volatile than the S&P 500 by 29.528%.

Nuvalent, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Glaukos Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuvalent, Inc. pays -- of its earnings as a dividend. Glaukos Corp. pays out -- of its earnings as a dividend.

Nuvalent, Inc. quarterly revenues are --, which are smaller than Glaukos Corp. quarterly revenues of $143.1M. Nuvalent, Inc.'s net income of -$122.4M is higher than Glaukos Corp.'s net income of -$133.7M. Notably, Nuvalent, Inc.'s price-to-earnings ratio is -- while Glaukos Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuvalent, Inc. is -- versus 13.55x for Glaukos Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Kodiak Sciences, Inc. has a net margin of -- compared to Nuvalent, Inc.'s net margin of --. Nuvalent, Inc.'s return on equity of -38.24% beat Kodiak Sciences, Inc.'s return on equity of -201.8%.

Nuvalent, Inc. has a consensus price target of $142.65, signalling upside risk potential of 41.94%. On the other hand Kodiak Sciences, Inc. has an analysts' consensus of $35.50 which suggests that it could grow by 40.43%. Given that Nuvalent, Inc. has higher upside potential than Kodiak Sciences, Inc., analysts believe Nuvalent, Inc. is more attractive than Kodiak Sciences, Inc..

Nuvalent, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Kodiak Sciences, Inc. has a beta of 2.640, suggesting its more volatile than the S&P 500 by 164.038%.

Nuvalent, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kodiak Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuvalent, Inc. pays -- of its earnings as a dividend. Kodiak Sciences, Inc. pays out -- of its earnings as a dividend.

Nuvalent, Inc. quarterly revenues are --, which are smaller than Kodiak Sciences, Inc. quarterly revenues of --. Nuvalent, Inc.'s net income of -$122.4M is lower than Kodiak Sciences, Inc.'s net income of -$61.5M. Notably, Nuvalent, Inc.'s price-to-earnings ratio is -- while Kodiak Sciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuvalent, Inc. is -- versus -- for Kodiak Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Neurocrine Biosciences, Inc. has a net margin of -- compared to Nuvalent, Inc.'s net margin of 19.08%. Nuvalent, Inc.'s return on equity of -38.24% beat Neurocrine Biosciences, Inc.'s return on equity of 17%.

Nuvalent, Inc. has a consensus price target of $142.65, signalling upside risk potential of 41.94%. On the other hand Neurocrine Biosciences, Inc. has an analysts' consensus of $176.89 which suggests that it could grow by 37.52%. Given that Nuvalent, Inc. has higher upside potential than Neurocrine Biosciences, Inc., analysts believe Nuvalent, Inc. is more attractive than Neurocrine Biosciences, Inc..

Nuvalent, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Neurocrine Biosciences, Inc. has a beta of 0.311, suggesting its less volatile than the S&P 500 by 68.878%.

Nuvalent, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Neurocrine Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuvalent, Inc. pays -- of its earnings as a dividend. Neurocrine Biosciences, Inc. pays out -- of its earnings as a dividend.

Nuvalent, Inc. quarterly revenues are --, which are smaller than Neurocrine Biosciences, Inc. quarterly revenues of $805.5M. Nuvalent, Inc.'s net income of -$122.4M is lower than Neurocrine Biosciences, Inc.'s net income of $153.7M. Notably, Nuvalent, Inc.'s price-to-earnings ratio is -- while Neurocrine Biosciences, Inc.'s PE ratio is 27.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuvalent, Inc. is -- versus 4.61x for Neurocrine Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals, Inc. has a net margin of -- compared to Nuvalent, Inc.'s net margin of -246.76%. Nuvalent, Inc.'s return on equity of -38.24% beat Vanda Pharmaceuticals, Inc.'s return on equity of -47.32%.

Nuvalent, Inc. has a consensus price target of $142.65, signalling upside risk potential of 41.94%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $13.63 which suggests that it could grow by 136.55%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than Nuvalent, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than Nuvalent, Inc..

Nuvalent, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.622, suggesting its less volatile than the S&P 500 by 37.837%.

Nuvalent, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuvalent, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Nuvalent, Inc. quarterly revenues are --, which are smaller than Vanda Pharmaceuticals, Inc. quarterly revenues of $57.2M. Nuvalent, Inc.'s net income of -$122.4M is higher than Vanda Pharmaceuticals, Inc.'s net income of -$141.2M. Notably, Nuvalent, Inc.'s price-to-earnings ratio is -- while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuvalent, Inc. is -- versus 1.57x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.